Companies / MSB

MESOBLAST LIMITED

ASX:MSBPharmaceuticals, Biotechnology & Life Sciences
1.30B shares on issueASX (delayed) · as of 28 July 2026$2.14price · delayed$2.88Bmarket cap · indicative
B
Dilution grade

Share count grew 14% in 24 months; 1 cash raise in 24 months; options/rights overhang 8% of shares

Cash runway25.9 quarters of funding
Share-count growth (24m)13.7%
Raise cadence (24m)1 cash raise
Options & rights overhang8.4% of shares
In-the-money supply0.0% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

MESOBLAST LIMITED's ordinary share count increased 13.7% between April 2024 and July 2026 to 1.30B shares. The company raised capital once in that period for total proceeds of A$260.0M, most recently in January 2025 for A$260.0M. Options and rights on issue could convert into 109M new shares, equal to 8.4% of the current share count, with 0% in the money. At the March 2026 quarter MESOBLAST reported A$115.9M in cash, representing 25.9 quarters of cover. One proposed securities issue (Appendix 3B) is pending, with an expected issue date in December 2026.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
8.4%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
25.9 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.30B per ASX (delayed) (28 July 2026).
1.17B1.22B1.27BDec 24Sept 25July 26Cash raise · 9 Jan 2025

Cash runway

25.9 qtrs
More than four quarters of funding at the recent spend rate.
$115.9M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
20 July 20263G · unquotedMSB : ORDINARY FULLY PAID1.30BAppendix 3G
20 July 20262A · quoted issueMSB : ORDINARY FULLY PAID1.30BAppendix 2A
14 July 20263G · unquotedMSB : ORDINARY FULLY PAID1.29BAppendix 3G
14 July 20263G · unquotedMSB : ORDINARY FULLY PAID1.29BAppendix 3G
14 July 20262A · quoted issueMSB : ORDINARY FULLY PAID1.30BAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 0 in the last 12 months

$260.0M
Capital raise
9 Jan 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

1 proposed issue pending — Appendix 3B lodged, securities not yet issued. New shares from these issues are not in the counts above until quoted.
Paid plan
Pending issue detail
Size, price, fees, broker and placement-capacity usage for each pending issue.
Join the waitlist

Options & convertible securities

8.4%
Total overhang · of current shares
0.0%
In the money · at current price
109.0M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
17 July 2026Dr Silviu ItescuOther1.9M1.9M$2.7M3Y notice
7 July 2026Dr Silviu ItescuOther79.0M18.2M—3Y notice
9 Apr 2026Gregory GeorgeBuy7.2M—$11.4M3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

24 July 2026Ceasing to be a substantial holder
21 July 2026Ceasing to be a substantial holder
20 July 2026Mesoblast CEO Makes Investment to Increase Share Ownership
20 July 2026Appendix 3Y - Silviu Itescu
20 July 2026Notification regarding unquoted securities - MSB
20 July 2026Application for quotation of securities - MSB
14 July 2026Notification of cessation of securities - MSB
14 July 2026Notification regarding unquoted securities - MSB
14 July 2026Application for quotation of securities - MSB
14 July 2026Notification regarding unquoted securities - MSB
14 July 2026Appendix 3Y - Silviu Itescu
14 July 2026$PPivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients
9 July 2026$PRyoncil Q4 Net Revenue of US$36M and US$115M for Full Year
30 June 2026Receives FDA BLA Filing Number and Requests Modular Review
29 June 2026Becoming a substantial holder
28 June 2026Ceasing to be a substantial holder
24 June 2026$PMesoblast Draws US$50M from Five-Year Non-Dilutive Facility
15 June 2026Becoming a substantial holder
11 June 2026Ceasing to be a substantial holder
2 June 2026ASX CEO Connect Presentation

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.